US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Inhibikase Therapeutics

News headline image
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Announces Expansion of Senior Leadership Team
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT
News headline image
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
Tickers IKT